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Metastasis is the leading cause of death for cancer patients. 
This multi-stage process requires tumour cells to survive in the 
circulation, extravasate at distant sites, then proliferate, and 
involves contributions from both the tumour cell and tumour 
microenvironment (‘host’, which includes stromal cells and the 
immune system 1). Studies suggest the early steps of the metastatic 
process are relatively efficient, with the post-extravasation 
regulation of tumour growth (‘colonisation’) being critical in 
determining metastatic outcome 2. Here we show the results of 
screening 810 mutant mouse lines using an in vivo assay to identify 
microenvironmental regulators of metastatic colonisation. We 
identify 23 genes, that when disrupted in mouse, modify the ability 
of tumour cells to establish metastatic foci, with 19 of these genes 
not previously demonstrated to play a role in metastasis. The largest 
reduction in pulmonary metastasis was observed in sphingosine-1-
phosphate (S1P) transporter Spinster Homolog 2 (Spns2)-deficient 
mice. We demonstrate a novel outcome of S1P-mediated regulation 
of lymphocyte trafficking, whereby deletion of Spns2, either globally 
or in a lymphatic endothelial-specific manner, creates a circulating 
lymphopenia and a higher percentage of effector T cells and NK cells 
present in the lung. This allows for potent tumour cell killing, and an 
overall decreased metastatic burden.  
 
To identify microenvironmental genes that regulate metastatic 
colonisation we performed an ‘experimental metastasis assay’ involving 
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intravenous injection of B16-F10 mouse metastatic melanoma cells, used 
previously in the development of checkpoint inhibitors such as CTLA4 and 
PD-1 3,4, and the assessment of pulmonary colonisation (Fig. 1a). The 
810 mutant mouse lines we assayed were randomly selected and cover a 
diverse range of molecular functions (Fig. 1b and SI Table 1). Using a 
stringent 2-stage selection process, we identified 23 mutant lines showing 
significantly decreased or increased numbers of pulmonary melanoma 
foci, defined as a ratio of ≤ 0.6 or ≥ 1.6 and P ≤ 0.0175 (Mann-Whitney 
test) for mutant mice versus wildtypes assayed concurrently (in the initial 
cohort assayed (Fig. 1a)), and P < 0.01 in an Integrative Data Analysis 
performed on 3 or more additional cohorts (Fig. 1c, SI Table 2 and 
Methods). Since these strains were extensively phenotyped 5, we were 
able to determine that alterations of immune-related phenotypic traits 
featured prominently in these 23 mutant lines (Fig. 1c), highlighting the 
key role of the immune system in microenvironmental regulation of 
metastasis. 
Of the 8 genes identified as suppressors of pulmonary metastases, 
two were members of the interferon regulatory family (IRF), important for 
immune function; loss of Irf1 or Irf7 increased pulmonary metastasis (as 
well as extra-pulmonary metastases in Irf1tm1a/tm1a mice), likely related to 
defects in their type-I IFN-dependent response 6,7. In contrast Irf5-deficient 
mice, with their largely intact type-I IFN response 8, showed no altered 
pulmonary metastasis phenotype (Extended Data Fig. 1). Similarly, the 
increased metastasis seen in p110 catalytic subunit of phosphoinositide 
3-kinase (Pik3cg)-deficient mice is likely related to the critical function of 
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this gene in multiple aspects of T cell, NK cell and neutrophil function 9,10, 
and the increased metastasis seen in immunoglobulin heavy chain 6 
(Ighm)-deficient mice is likely due to their multiple immune system 
abnormalities 11. In contrast, very little is known about the other four genes 
we identified as microenvironmental suppressors of metastasis, namely 
Abhd17a, Dph6, Slc9a3r2 and Rnf10, which represent novel factors for 
further studies. Of the 15 mutant mouse lines we identified as having 
decreased pulmonary melanoma colonies, four have been previously 
described as having roles in regulating metastasis; Entpd1 (Cd39), 
Nbeal2, Cybb and Hsp90aa1, contributing to regulatory T-cell control of 
NK cells 12, platelet α-granule function 13, generation of phagocyte-derived 
oxygen radicals 14 and the chaperoning of client proteins involved in 
tumour progression 15, respectively. 
We focused on the sphingosine-1-phosphate (S1P) transporter 
Spinster homolog 2 (Spns2), as Spns2tm1a/tm1a mice showed the greatest 
suppression in the number of pulmonary metastatic melanoma foci, with 
Spns2tm1a/+ mice showing an intermediate phenotype (Fig. 2a). Further, 
Spns2tm1a/tm1a mice showed reduced numbers of foci in the lungs after tail 
vein administration of lung CMT-167, colorectal MC-38 or breast 
EO771.LMB cancer cells (Fig. 2b), and decreased spontaneous 
pulmonary metastasis (both in number and size of metastatic foci) after 
subcutaneous administration of HCmel12-mCherry melanoma cells (Fig. 
2c and Extended Data Fig. 2a). In contrast, there was no difference in 
the growth rate of the primary tumour between wildtype and Spns2tm1a/tm1a 
mice, either for HCmel12-mCherry melanoma cells or B16-BL6 melanoma 
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cells, and no difference in the spontaneous incidence of cancer in aged 
wildtype and Spns2tm1a/tm1a mice (Extended Data Fig. 2b-d). Tail vein 
administration of transformed melanocyte WT31 cells (Fig. 2d) and intra-
splenic administration of B16-F10 cells (Fig. 2e) showed a reduced 
number of foci in the livers of Spns2tm1a/tm1a mice, suggesting the 
resistance to metastatic colonisation is not pulmonary-restricted.  
S1P is a bioactive lipid mediator that plays important roles in 
diverse cellular functions such as cell proliferation, differentiation, 
migration and tumourigenesis 16. Previous studies have demonstrated 
SPNS2 functions as a cell-surface S1P transporter that allows intracellular 
S1P to be secreted into the blood and lymph 17-19. In agreement with 
previous studies 17,19, S1P was decreased in serum and increased in 
lungs of Spns2tm1a/tm1a mice (Extended Data Fig. 3). Although 
extracellular S1P is a key regulator of endothelial barrier homeostasis 20, 
vascular permeability/extravasation of Evans Blue dye in Spns2tm1a/tm1a 
mice was the same as controls (Fig. 2f), as was the arrival of B16-F10 
cells in the lung 90 minutes after tail vein administration (Fig. 2g). 
However, a significant increase in the number of pulmonary B16-F10 cells 
showing evidence of apoptosis was observed after 12 hours (Fig. 2h), 
suggesting that the lungs of Spns2tm1a/tm1a mice represent a hostile 
environment for tumour cell engraftment. RNA-seq analysis comparing 
viable B16-F10 cells isolated from lungs 24 hours after their administration 
identified nine differentially expressed (up-regulated) genes (Source Data 
Table 1); six of these genes (Pla2g16, Epsti1, Traf1, Glipr2, Marcksl1 and 
Ccl5) are known to be involved in pro-metastatic phenotypes of tumour 
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cells, and H2-Q7-positive B16-F10 cells have been shown to be targeted 
by both NK and cytotoxic T-cells 21. Thus, the transcriptional profile of B16-
F10 cells from Spns2tm1a/tm1a lungs suggests they are upregulating genes 
to facilitate their survival in a hostile environment, whilst at the same time 
provoking activation of the immune system.  
One of the most notable effects of S1P is the regulation of 
lymphocyte trafficking 22. SPNS2 has been reported to function as an S1P 
transporter in endothelial cells but not in erythrocytes or platelets 17. In 
agreement with others 17-19,23, Spns2tm1a/tm1a mice have a profound 
reduction in circulating T and B cells, with all other leukocyte (including 
NK cells) and blood cell lineages unaffected (Extended Data Fig. 4a-c). 
In the lung, the percentage of T cells was significantly reduced with a small 
reduction in the B cell percentage and increased NK cells (Fig. 3a), with 
similar phenotypes observed in the liver (Extended Data Fig. 4d). 
Consistent with Spns2 expression in endothelial cells 17, bone marrow 
chimeras showed a lymphocyte and metastatic colonisation phenotype 
identical to the genotype of the host (Fig. 3b and Extended Data Fig. 4e-
f), confirming that non-hematopoietic stroma regulates these 
observations. Expression of Spns2 by endothelial cells is required for the 
maintenance of an S1P gradient in the lymph that is critical for regulating 
lymphocyte circulation 18. In agreement with this, we showed that mice 
with lymphatic endothelial cell (LEC)-specific deletion of Spns2 
(Spns2tm1c/tm1c; Lyve1cre/+ mice) did not have altered serum or lung S1P 
levels (Extended Data Fig. 5a-b), yet displayed lymphopenia in the blood 
(Fig. 3c), lungs (Fig. 3d) and other tissues examined (Extended Data 
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Fig. 5c). Critically, this resulted in a decreased number of pulmonary 
metastasis in Spns2tm1c/tm1c; Lyve1cre/+ mice administered either B16-F10 
or MC-38 cells (Fig. 3e and Extended Data Fig. 5d).  
We next set out to establish the contribution of SPNS2 to the 
pulmonary immune microenvironment. S1P-S1PR1 signalling is essential 
for the recirculation of naive T-cells, however, memory T cells 
downregulate S1PR1 expression and rely on chemokine receptors for 
trafficking 24. In contrast NK cell trafficking in response to S1P requires 
S1PR5 not S1PR1 25. In agreement with this differential requirement of 
S1P for trafficking, Spns2tm1a/tm1a mice showed a significantly higher 
percentage of anti-tumoral effector memory T cells (CD44hiCD62Llo) 
relative to immune suppressive regulatory T cells (CD4+CD25+) thus 
providing an enhanced effector:regulatory T cell ratio (Fig. 3f and 
Extended Data Fig. 6a-b), with the same observed in Spns2tm1c/tm1c; 
Lyve1cre/+ mice (Fig. 3g and Extended Data Fig. 6c-d). An increased 
proportion of activated T cells (KLRG1+, CD69+ and CXCR3+) were also 
observed in the lungs of Spns2tm1a/tm1a and Spns2tm1c/tm1c; Lyve1cre/+ mice 
(Fig. 3h-i), with a similar phenotype seen in the liver (Extended data Fig. 
7). 
Consistent with this activated phenotype, we performed ex vivo 
restimulation assays, where T cells were isolated from the lungs of 
Spns2tm1a/tm1a and control mice 5 days after in vivo activation with B16-
F10 cells. Using pharmacological stimulation both CD4 and CD8 T cells 
from Spns2tm1a/tm1a mice showed an enhanced degranulation response 
(cell surface expression of CD107a/LAMP1), and increased intracellular 
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interferon-γ (IFN-γ) relative to control mice (Fig. 4a-b). Interestingly, only 
CD8 T cells demonstrated enhanced degranulation when co-cultured with 
B16-F10 cells ex vivo suggestive of the presence of an improved antigen-
specific response towards B16-F10 (Fig. 4c). This functionally resulted in 
enhanced B16-F10 target cell killing in an ex vivo cytotoxicity assay (Fig. 
4d), and increased IFN-γ in lung lysates from B16-F10-stimulated 
Spns2tm1a/tm1a (Fig. 4e), and Spns2tm1c/tm1c; Lyve1cre/+ mice (Fig. 4f). 
Similarly, increased IFN-γ was also observed in lung lysates from MC-38-
stimulated Spns2tm1a/tm1a mice (Extended Data Fig. 8a) indicating that this 
is not a B16-F10 restricted phenomenon. Although there was a significant 
increase in the relative proportion of NK cells in the lung, no difference in 
NK cell function could be observed ex vivo in Spns2tm1a/tm1a mice (Fig. 4a-
b), in agreement with normal NK cell KLRG1, CD69 and CXCR3 
expression in both Spns2tm1a/tm1a and Spns2tm1c/tm1c; Lyve1Cre/+ mice 
(Extended Data Fig. 8b-c). 
To determine if the beneficial effects of Spns2 in regulating 
metastatic colonisation could be mediated by CD8 T cells, we performed 
in vivo depletion experiments using anti-CD8 antibodies. However, 
paradoxically, depletion of CD8 T cells (or all T and B cells, such as in 
Rag1 knockout mice) has previously been shown to decrease B16-F10 
pulmonary metastasis (but not primary tumour growth); this phenomenon 
has been explained by the ‘pro-tumoural’ phenotype of CD8 T cells prior 
to tumour cell exposure versus the ‘anti-tumoural’ effect of antigen-
specific CD8 T cells 26. Indeed, we replicated this finding observing 
decreased pulmonary B16-F10 metastases in CD8-depleted wildtype 
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mice (Fig. 4g; and Rag2 knockout mice, Extended Data Fig. 9), however, 
a genotype-specific effect was still observed in Spns2tm1a/tm1a mice, 
suggesting the involvement of additional cell types in the regulation of 
metastatic colonisation. Given that we observed compensatory NK cell 
activation (CD69+) in the lungs of CD8-depleted Spns2tm1a/tm1a mice (Fig. 
4h), we hypothesized NK cells could be responsible for the significantly 
reduced metastasis count compared to wildtypes. To explore this 
observation further, we performed NK cell depletion, resulting in increased 
B16-F10 metastases as reported previously 26, however Spns2tm1a/tm1a 
mice still showed a significantly reduced number of metastatic foci 
compared to wildtypes (Fig. 4i), in agreement with the enhanced CD8 
response to B16-F10 cells observed ex vivo (Fig. 4c). To demonstrate the 
dual cellular identity responsible for protection in Spns2tm1a/tm1a we co-
depleted NK and CD8 cells in vivo restoring the number of metastatic foci 
observed in Spns2tm1a/tm1a mice to those of wildtype (Fig 4i). Thus, we 
demonstrate that both CD8 T-cells and NK cells can contribute to the 
reduced pulmonary metastatic burden observed in Spns2tm1a/tm1a mice. An 
alteration of lymphatic endothelial cell function or lung sphingolipid levels 
in Spns2-deficient mice may also contribute to the reduced pulmonary 
metastatic burden we observe. 
Finally we sought to manipulate the S1P system pharmacologically 
by inhibiting the S1P lyase that degrades S1P using 4’-deoxypyridoxine 
(DOP), a compound previously shown to increase lymphoid tissue S1P 
levels and induce a circulating lymphopenia 22. DOP treatment 
phenocopied the immune and pulmonary metastasis phenotype of 
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Spns2tm1a/tm1a mice (Extended Data Fig. 10), further validating the 
importance of the S1P axis in control of pulmonary metastatic burden. 
Importantly modulation of SPNS2 could be a more favourable approach 
than the S1P-blocking antibody Sphingomab27,28 or the prodrug FTY720 
24 (which is phosphorylated in vivo to a functional antagonist of S1PR1) 
as these interventions increase regulatory T cell activity, suppress 
proliferation of effector T cells 29,30, and also increase vascular 
permeability 18. Furthermore, as lymphatic endothelial cell-specific 
deletion of Spns2 is sufficient to regulate lymphocyte circulation to allow 
a higher percentage of effector T cells and NK cells in the lung (and liver) 
and more tumour cell killing, targeting SPNS2 is potentially a more 
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Figure 1 | Identification of microenvironmental regulators of metastatic 
colonisation of the lung. a, Experimental model (schematic) and results from 
stage 1 of the screen: experimental metastasis assay performed on 810 mutant 
mouse lines (detailed in the Extended Methods). Those lines with a metastatic 
ratio of ≤ 0.6 (red box) or ≥ 1.6 (green box) and Mann-Whitney test P ≤ 0.0175 
were taken forward to stage 2 (see below). b, Molecular function gene ontology 
annotation of the 810 mutant mouse lines screened as detailed in Materials and 
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Methods. c, Top level mammalian phenotype ontology terms for the 23 
statistically significant genes following an Integrative Data Analysis of 
experimental metastasis assay results from three or more additional cohorts 
(green is increased metastasis and red is decreased). In the heatmap red boxes 
indicate a phenodeviant call, and blue no phenotype annotated (either no 
phenotype detected or not assayed) as detailed in Methods.  
 
Figure 2 | Ability of Spns2-deficient mice to regulate metastatic 
colonisation. a, Experimental metastasis assay using B16-F10 cells in +/+ 
(blue), tm1a/+ (green) and tm1a/tm1a (red) male mice, with representative 
images. b, Experimental metastasis assay using CMT-167 (+/+, n=8; 
tm1a/tm1a, n=6 female mice), MC-38 (+/+, n=10; tm1a/tm1a, n=5 male mice) 
and EO771.LMB cells (+/+, n=12; tm1a/tm1a, n=5 female mice). c, 
Spontaneous metastasis assay using HCmel12-mCherry melanoma cells in 
male mice (n=10 per genotype), with representative fluorescent images (lines 
indicate the edge of the lungs). d,  Experimental metastasis assay using WT31 
transformed melanocytes in +/+ (n=18) and tm1a/tm1a (n=6) male mice. e, 
Intra-splenic administration of B16-F10 cells in +/+ (n=16) and tm1a/tm1a 
(n=15) female mice. f, Micrograms of extravasated Evans Blue dye in the lungs 
of +/+ and tm1a/tm1a male mice. g, Number of CFSE-labelled B16-F10 cells 
present in the lungs of female mice 90 min after administration. h, Levels of 
apoptosis in B16-F10-mCherry cells 12 hours after administration to male mice. 
Shown are representative data from 2 (CMT-167, b) or 3 independent 
experiments (a, b (MC-38 and EO771.LMB), d, f-h) or cumulative results of 2 
independent experiments (c, e) with mean ± SEM (b - e) or symbols 
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representing individual mice with horizontal bar at the mean (a, f-h). P values 
are indicated from one-way ANOVA with Sidak's multiple comparisons 
adjusting for multiple testing (a), Mann-Whitney test (b-d), one-tailed unpaired 
t test (e) or two-tailed unpaired t test with Welch’s correction (f-h). 
 
Figure 3 | Characterisation of the lymphocyte composition and phenotype 
in Spns2 mice. a, The percentage of lymphocyte subsets in the lungs of +/+ 
and tm1a/tm1a female mice. b, Number of metastases in B16-F10-dosed male 
bone marrow chimaeras (genotypes: +/+ (WT) and tm1a/tm1a (KO)). c, 
Numbers of lymphocytes in the blood of control and tm1c/tm1c; Lyve1cre/+ male 
mice. d, The percentage of lymphocyte subsets in the lungs of control and 
tm1c/tm1c; Lyve1cre/+ male mice (two-tailed unpaired t test adjusted by the 
Holm-Sidak method with alpha set to 5%). e, Experimental metastasis assay 
using B16-F10 cells in control and tm1c/tm1c; Lyve1cre/+  female mice. f-i, T cell 
subset populations in the lungs of +/+ and tm1a/tm1a female mice or control 
and tm1c/tm1c; Lyve1cre/+ male mice. Shown are representative data from 2 (b) 
or 3 independent experiments (a, c-i) with symbols representing individual mice 
with horizontal bar at the mean (a-i). P values are indicated from two-tailed 
unpaired t test adjusted by the Holm-Sidak method with alpha set to 5% (a, c-
d, f-i) or Mann-Whitney test (b, e). 
 
 
Figure 4 | Lymphocyte activity within the lungs of Spns2 mice. a-b, Ex vivo 
restimulation (PMA/ionomycin) of pulmonary leukocytes from B16-F10-
stimulated +/+ and tm1a/tm1a female mice. c, Degranulation assay on 
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pulmonary leukocytes from B16-F10-stimulated +/+ and tm1a/tm1a female 
mice in response to in vitro restimulation with B16-F10. d, Cytotoxicity assay 
on pulmonary leukocytes from B16-F10-stimulated +/+ and tm1a/tm1a female 
mice (n=8 per genotype). e-f, Measurement of IFN-γ in lungs of B16-F10-
stimulated +/+ and tm1a/tm1a female mice, and control and tm1c/tm1c; 
Lyve1cre/+ male mice. g, Experimental metastasis assay using B16-F10 cells in 
+/+ and tm1a/tm1a female mice treated with either isotype or anti-CD8 
antibody. h, The proportion of activated (CD69+) NK cells present in the lungs 
of +/+ and tm1a/tm1a female mice dosed with isotype or anti-CD8 antibody. i, 
Experimental metastasis assay using B16-F10 cells in +/+ and tm1a/tm1a male 
mice treated with either isotype, anti-NK1.1 or anti-NK1.1 and CD8 antibody. 
Shown are representative data from 3 independent experiments with symbols 
representing individual mice with horizontal bar at the mean (a-c, e-i) or mean 
± SEM (d). P values are indicated from two-tailed unpaired t test adjusted by 
the Holm-Sidak method with alpha set to 5% (a-b), two-tailed unpaired t test 
with Welch’s correction (c, e-f, h), two-way repeated measures ANOVA with 
Sidak’s multiple comparisons test for each effector:target ratio (d) or Mann-
Whitney test (g, i). 
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METHODS 
 
Mice. The generation and genotyping of Spns2tm1a(KOMP)Wtsi (referred to as 
tm1a/tm1a)23, Spns2tm1b(KOMP)Wtsi, Lyve1tm1.1(EGFP/cre)Cys/J (referred to as 
Lyve1cre) mice 31 and Rag2tm1Fwa mice 32 have been described previously. 
Spns2tm1c(KOMP)Wtsi (referred to as tm1c/tm1c) mice were generated from 
crossing Spns2tm1a(KOMP)Wtsi mice with Flp-deleter mice 33 and crossed to 
Lyve1cre mice to generate experimental mice (tm1c/tm1c; Lyve1cre/+) with 
littermates used as controls (tm1c/+; Lyve1+/+and tm1c/tm1c; Lyve1+/+; referred 
to as “controls”). The care and use of all mice in this study were in accordance 
with the UK Animals in Science Regulation Unit’s Code of Practice for the 
Housing and Care of Animals Bred, Supplied or Used for Scientific Purposes, 
the Animals (Scientific Procedures) Act (ASPA) 1986 Amendment Regulations 
2012, and all procedures were carried out under a Home Office Project licence, 
which was reviewed and approved by the Sanger Institute’s Animal Welfare 
and Ethical Review Body. Housing and husbandry conditions were as 
described previously 34, with the exceptions that a cage density of 1-6 mice per 
cage was used and mice were maintained on Mouse Breeders Diet (Lab Diets, 
5021-3) throughout the study. Unless specified otherwise, all mice were used 
at 6-12 weeks of age.  
 
General Experimental Design. For the majority of experiments, random 
allocation to treatment group was achieved through the process of Mendelian 
inheritance, with age- and sex-matched mice being selected across different 
litters and matings (to minimise potential litter and/or cage effects). The two 
exceptions are the NK cell depletion study and bone marrow chimaera study; 
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in these studies Mendelian inheritance was used to randomise assignment of 
animals to a genotype group and then within this block alternate allocation was 
used to assign treatment. Unless specified otherwise, the researcher was not 
blinded to the identity of the genotype and/or treatment of a mouse during any 
procedures due to this being written on the cage card. Pilot experiments were 
performed to determine sample size with adequate statistical power for all 
studies except the high throughput screen where this this was not possible due 
to the scale of breeding that would be required. For each procedure, exclusion 
criteria used are listed where applicable in the materials and methods. If no 
exclusion criteria are detailed, all data were included. The manuscript was 
prepared to meet ARRIVE reporting guidelines 35. 
 
Cell lines. The mouse melanoma B16-F10 cell line was purchased from ATCC 
(CRL-6475™) and the highly metastatic mouse melanoma B16-BL6 cell line 
was purchased from the University of Texas, MD Anderson Cancer Center and 
authenticated by whole genome and transcriptome sequencing. The mouse 
lung carcinoma CMT-167 cell line was purchased from Sigma-Aldrich 
(10032302) and the other cell lines were obtained from the laboratories that 
generated them. Specifically, the metastatic mouse colorectal MC-38 cell line 
36 was a kind gift from Lubor Borsig (University of Zurich, Switzerland), the 
metastatic mouse mammary cancer EO771.LMB cell line 37 was a kind gift from 
Robin L. Anderson (Peter MacCallum Cancer Centre, Australia), the metastatic 
HCmel12-mCherry melanoma cell line 38 was a kind gift from Thomas Tuting 
(University of Bonn, Germany), and the transformed mouse melanocyte WT31 
cell line (Tyr::NrasQ61K/°; INK4a-/-) 39 was a kind gift from Owen Sansom 
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(Beatson Institute for Cancer Research, Scotland). None of the cell lines used 
appear in the International Cell Line Authentication Committee database. All 
cells (apart from WT31 cells) were maintained in DMEM with 10% (v/v) foetal 
calf serum and 2 mM glutamine, 100 U/ mL penicillin/streptomycin (with the 
addition of 20 mM HEPES for EO771.LMB cells) at 37oC, 5% CO2. WT31 cells 
were maintained in RPMI with 10% (v/v) foetal calf serum and 2 mM glutamine, 
100 U/mL penicillin/streptomycin at 37oC, 5% CO2. All cell lines were screened 
for the presence of mycoplasma and mouse pathogens (at Charles River 
Laboratories, USA) prior to culturing and never cultured for more than 5 
passages. The B16-F10-mCherry cells, stably expressing mCherry, were 
generated by co-transfection of B16-F10 cells with 4.5 μg of PB-CAGG-LUC-
2A-mCherry-PURO-PB plasmid (a kind gift from David Ryan, Wellcome Trust 
Sanger Institute) and 0.5 of PBase-expressing plasmid using Fugene HD 
(Promega) according to the manufacturer’s recommendations. After selection 
in 5 μg/mL puromycin (Gibco BRL) for 10 days, when cell sorting was performed 
(MoFlo™ XDP, Beckman Coulter) to select for those cells expressing high 
levels of mCherry and was maintained in 5 μg/mL puromycin. 
 
Experimental metastasis assay. B16-F10 (4x105), CMT-167 (1x105), MC-38 
(4x105), EO771.LMB (4x105) or WT31 (2.5x106) cells resuspended in 0.1 mL 
PBS were injected into the tail vein of 6- to 12-week-old sex-matched syngeneic 
control and mutant mice. After 10 days (or 30 days if WT31 cells were used) 
the mice were sacrificed, their lungs removed (or livers removed if WT31 cells 
were used), and the number of metastatic foci counted macroscopically (for 
B16-F10 and WT31 cells) or microscopically from formalin-fixed H&E-stained 
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sections by a pathologist (for CMT-167, MC-38 and EO771.LMB cells; the 
pathologist was blinded to the genotypes of the samples). For intrasplenic 
injections of B16-F10 melanoma cells the mice were anaesthetised under 
isofluorane gas, with laparotomy performed to expose the spleen. B16-F10 
cells (1x104) resuspended in 0.03 mL PBS were injected into the tail of the 
spleen, after which surgical incisions sutured and surgical clips applied. 
Animals monitored throughout recovery with dietary support and analgesia 
(Rimadyl 100 µg/mL ad libitum) provided. After 14 days, the mice were 
sacrificed, their livers removed, and the number of metastatic foci counted 
macroscopically. 
 
Metastatic colonization screen. The experimental metastasis assay (detailed 
above) was performed by administering 4x105 B16-F10 cells to age- and sex-
matched wildtype and mutant mice. The mice were 6-12 weeks old (typically 6-
8 weeks) at time of dosing and dosing cohorts typically consisted of 12-24 
control mice with 3-5 different mutant alleles being screened (3-8 mutant mice 
per allele). To ensure consistency, preparation of the cells, administration into 
the tail vein and counting of pulmonary metastatic foci were performed by the 
same individual. To ensure a high level of accuracy, a two-stage process was 
implemented, with final calls only being made after data had been collected 
from multiple independent cohorts (the data from all mice were included in the 
analysis except for when the full 0.1 mL of cell suspension was not successfully 
administered due to difficulties at the time of injection). The first stage was a 
high throughput process to identify lines of potential interest for the second 
stage; in this stage, mutant lines with a ‘metastatic ratio’ (mean number of 
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metastatic foci in the mutant cohort divided by mean number of metastatic foci 
in the wildtype cohort) ≤ 0.6 or ≥ 1.6 and P ≤ 0.0175 in the Mann-Whitney test 
(a subsequent analysis estimated a false discovery rate of 15%) progressed to 
the second stage. In the second stage, at least 3 additional cohort(s) of mice 
(of both sexes) were independently studied and the data combined into an 
Integrative data analysis (IDA) as detailed in the Statistics section. 
 
Bone marrow chimaeras. Wildtype and tm1a/tm1a mice were given 2 x 4.2 
Gy whole body irradiation followed by tail vein administration of 3x106 bone 
marrow cells from either wildtype or tm1a/tm1a mice. Six weeks post-transplant 
a tail vein blood sample was taken from the mice for assessing the relative 
proportion of CD45.1 versus CD45.2 cells and number of T and B lymphocytes 
present in the peripheral blood and two days later an experimental metastasis 
assay performed. 
 
In vivo depletion studies. Mice were given as intra-peritoneal dose of 
antibodies (anti-CD8 [clone YTS169.4)], rat IgG2b isotype control [clone LTF-
2]), anti-NK1.1 [clone PK136], mouse IgG2a [clone C1.18.4]), 200 μg in 0.1 mL 
PBS on day -3, 0 and +5, with B16-F10 cells tail vein administered on day 0 
(CD8-depletion mice were dosed with 4x105 B16-F10 cells; NK and NK/CD8-
depletion mice were dosed with 2x105 B16-F10 cells). Tail vein blood samples 
were collected from all mice on day +1 to confirm the depletion was effective. 
All antibodies were “InVivoMAb” from BioXCell. 
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S1P lyase inhibitor studies. For S1P lyase inhibitor studies, the mice were 
either given glucose (10 g/L) or glucose plus 4’ deoxypyridoxine (DOP, 30 mg/L; 
Sigma) in their drinking water 1 week prior to any experimentation (with mice 
remaining on it for the duration of the experiment) 22. 
 
Primary tumour growth studies. For examination of orthotopic tumour 
growth, wildtype and tm1a/tm1a male and female mice at 6-8 weeks of age 
were subcutaneously administered 2.5x103 B16-BL6 melanoma cells in the 
flank. The developing tumours were measured every second day and if they 
had reached (or were very close to) 2cm2 on the day of measurement the mice 
were immediately culled (no tumour was ever more than 2.4cm2), as approved 
by the Home Office Inspector under the authority of ASPA.  
 
Spontaneous metastasis assay. Wildtype and tm1a/tm1a mice were 
subcutaneously dosed with 2x105 HCmel12-mCherry melanoma cells and the 
resulting tumour growth was monitored by inspection and palpation. The size 
of the tumour was measured weekly using vernier calipers and recorded as 
mean diameter. Mice were killed when progressively growing melanomas 
exceeded 20 mm in size and tissues collected for further analyses (in 
accordance with institutional and national guidelines for the care and use of 
laboratory animals with approval by the local government authorities (LANUV, 
NRW, Germany)). The number of macroscopically visible metastases present 
on the lung surface were counted by two independent investigators in a blinded 
fashion. 
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Preparation of tissue cell suspensions. Mice were perfused with 20 mL 
phosphate buffered saline (PBS) by cardiac puncture and the tissues were 
disrupted in C tubes using program m_lung_01 with an gentleMACS (Miltenyi 
Biotec) in Hanks Balanced Salt solution (HBSS) containing calcium and 
magnesium. Liberase DL (Collagenase with low dispase content, Roche, 
Burgess Hill, UK) was added to a final concentration of 0.1 U/mL and incubated 
for 30 min at 37oC. The tubes were then processed using program m_lung_02 
and DNase (0.1 mg/mL) was added for a further 30 min at 37oC. The resulting 
cell suspension was centrifuged at 400 x g for 5 min, resuspended in 2 mL 
FACS buffer (D-PBS without calcium and magnesium containing 2 mM EDTA, 
0.5% fetal calf serum and 0.09% sodium azide), passed through a 30 μm cell 
strainer and analysed on the flow cytometer. For determining the number or 
viability of melanoma cells present in the lungs of mice, the mice were dosed 
with either 1x106 B16-F10 cells labelled with 10 μM CFSE (Molecular Probes, 
Invitrogen) at 90 min prior to perfusion or 1x106 B16-F10-mCherry cells at 12 
hrs prior to perfusion. In each case, the lung cell suspension was analysed on 
the flow cytometer. For lung/liver leukocyte analysis, the leukocytes were 
enriched from other cell types in the cell suspension on a Percoll™ 
discontinuous gradient (67.5%/44%) and washed three times with FACS buffer. 
Single cell suspensions from spleen and lymph nodes (pooled inguinal) were 
prepared using frosted end of microscope slides in FACS buffer. Red blood 
cells were lysed from spleen samples by the addition of 2 mL 1x PharmLyse 
(BD Biosciences) for 90 seconds at room temperature then stopped by the 
addition of 10 mL FACS buffer. Both spleen and lymph node samples were 
passed through a 30 μm cell strainer prior to staining. ‘Naïve’ mice were those 
  26 
that had not been administered B16-F10 cells and ‘stimulated’ mice were those 
that had been tail vein administered B16-F10 cells 3 or 5 days prior to analysis 
as indicated in the figure legend. 
 
FACS immunostaining. Samples were blocked with 1 μg of Mouse BD FC 
Block™ (anti CD16/32, clone 2.4G2, BD Biosciences) for 10 min prior to 
addition of multicolour antibody cocktails using titrated amounts to give 
saturating binding (see SI Table 3 for more details). After washing, cells were 
stained with a viability dye (Live/Dead Blue, Invitrogen, 1 in 1000 dilution in 
PBS) for 10 min at room temperature before being washed prior to acquisition. 
For apoptosis determination lung preparations were prepared as above and 
were stained with Caspglow reagent (eBioscience UK) according to the 
manufacturers instructions for 1 hr at 37oC. Cells were washed with Annexin 
binding buffer and stained with Annexin V-APC (both BD Biosciences) 
according to the manufacturers instructions for 15 min at room temperature. 
Cells were washed with Annexin binding buffer and resuspended Annexin V 
binding buffer containing 1 μg/mL DAPI (Life Technologies) prior to acquisition. 
For the determination of absolute cell counts of leukocyte populations, whole 
blood was counted with a haematology analyser (Scil Vetabc) and the white 
blood cell count was used to derive the cells/μL blood with the immune cell 
populations as % of leukocytes. 
 
Lung leukocyte cytotoxicity. Leukocytes were prepared from perfused lungs 
5 days post B16-F10 injection as described in ‘experimental metastasis assay’ 
above. B16-F10 target cells were labelled with 1 μM CFSE (Molecular Probes, 
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Invitrogen). Target cells and lung leukocytes were added to 96 well round 
bottom plates at effector to target ratios indicated for four hours at 37oC in 
complete DMEM medium (prepared as described in cell lines section). The cells 
were washed twice with ice-cold PBS then resuspended in 100 μL Live/Dead 
far red (Invitrogen, 1 in 1000 dilution in PBS) for 10 min at room temperature. 
Cells were washed twice and resuspended in BD Cell Fix for 10 min at room 
temperature and washed twice with FACS buffer, prior to acquisition where 
2,000 target cells were collected. Cytotoxicity was calculated according to the 
following equation [% of dead target cells with effector cells] – [% of dead target 
cells with no effector cells added]. 
 
Leukocyte degranulation and IFN-γ production. Leukocytes were prepared 
from perfused lungs 5 days post B16-F10 injection as described in 
‘experimental metastasis assay’ above. Cells were stimulated with target cells 
(B16-F10 at effector to target ratio of 2.5:1) or phorbol myristate acetate (PMA) 
and ionomycin (100 ng/mL and 150 ng/mL, respectively both Sigma-Aldrich). 
Cells and stimulus were added to 96 well round bottom plates in the presence 
of anti-CD107a antibody and BD GolgiStop™ (monensin, final concentration 2 
μM) in complete DMEM medium for four hours at 37oC. The plates were 
washed twice with ice-cold FACS buffer before blocking then staining with anti-
TCRβ, CD45, NK1.1 and CD8α antibodies. Cells were then stained with a 
fixable viability indicator (Live/Dead Blue, Invitrogen) prior to intracellular 
staining for IFN-γ according to standard methods and analysed by flow 
cytometry where a minimum of 50,000 CD45+ alive leukocyte events were 
collected. CD107a and IFN-γ gates were set on unstimulated leukocyte 
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samples and specific degranulation or intracellular IFN-γ staining was 
calculated by subtracting the leukocyte alone unstimulated values from the 
treated values. 
 
Flow cytometry. All samples were analysed on a LSR II or LSRFortessa™ 
(both BD Biosciences) that were standardised using BD Cytometer Setup and 
Tracking beads and software. Compensation was determined using Ultracomp 
eBeads (eBioscience) for all antibodies and ArC amide binding beads 
(Invitrogen) for live/dead stains. Data acquisition was controlled with BD 
FACSDiva v6.3 or v8.0.1 software. For the analysis of B16-F10 apoptosis a 
threshold was applied to the mCherry channel (561nm laser 610/30 BP) to 
exclude 90% of the lung cells. For the analysis of cytotoxicity a threshold was 
applied to the CFSE channel (488nm laser 530/30 BP) to exclude 90% of the 
lung leukocytes. In both cases these were established using B16-F10 mCherry 
or CFSE labelled B16-F10 cells. In all other cases a FSC-A threshold was used 
to exclude debris. All samples were analysed using FlowJo 10.7 and were 
analysed genotype and/or treatment blind. For all phenotyping data doublets 
were excluded using FSC-A versus FSC-H gates, sample acquisition issues 
(such as clumps and unstable event rate) were excluded using a time gate 
against a fluorescent parameter that was off the laser with the longest time 
delay, dead cells were excluded from all tissue analysis using a viability 
indicator and debris excluded with FSC-A versus SSC-A gates. A leukocyte 
gate was set with CD45 and SSC-A and all cell subsets are reported as the 
percentage of this parent gate. T cells were defined as TCRγδ- CD3+ NK1.1- or 
TCRβ+ NK1.1- with CD4+ and CD8+ gates defined on this parent population, NK 
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cells defined as NK1.1+ CD3- or TCR- and B cells defined as CD19+. T and NK 
cell phenotypes were determined using fluorescent minus one controls to 
establish gating.  Data from a sample was excluded if there were insufficient 
events in the parent gate to allow analysis, for example if there were less than 
50,000 CD45+ alive leukocytes in lung phenotyping data this was excluded from 
the dataset. 
 
Lung IFN-γ determination. Five days post-B16-F10 injection as described in 
‘experimental metastasis assay’ above, lungs were saline perfused and 
homogenised in Tris buffered saline with 0.5% Triton X100 using M tubes and 
a gentleMACS (Miltenyi Biotec) with program protein_01. Samples were 
cleared by centrifugation for 10 min 20,000xg at 4oC. IFN-γ levels in the lung 
lysates were determined using a Ready Set Go ELISA kit (eBioscience, 
Hatfield, UK) according to the manufacturer’s instructions. 
 
Transcriptome sequencing. Wildtype and Spns2 homozygous mice tail vein 
dosed with 1x106 B16-F10-mCherry cells were sacrificed after 24 hrs and lung 
cell suspensions prepared as described above. Using a cell sorter (MoFlo™ 
XDP), B16-F10-mCherry cells were identified after displaying in a bivariate plot 
of SSC-log versus mCherry by gating on high forward scatter versus side 
scatter to exclude some debris and dead cells and positively sorted. RNA was 
extracted from the sorted cells using the RNeasy Mini kit (Qiagen), according 
to the manufacturer’s instructions and used to generate cDNA using the Smart-
seq2 protocol 40,41. Multiplexed sequencing libraries were generated from 
amplified cDNA using Nextera XT (Illumina). The multiplexed mRNAseq 
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libraries were pooled and sequenced across multiple lanes on the Illumina 
Hiseq 2000 (v3). Paired-end 100 bp reads were aligned with STAR version 
2.3.0 42 allowing a minimum and maximum intron size of 50-500000 bp, 
respectively. STAR genome index files were generated using a GTF file 
corresponding to gene models from ENSEMBL version 74 and reference 
genome version GRCm38.  Read counting was performed with htseq-count 
from the HTSeq package (version 0.5.4p5) 43. The htseq-count software was 
run with the options ‘intersection-nonempty’ mode, non-stranded, minimum 
quality 10, and ‘exon’ was used as the feature type, with ‘gene_id’ as the GTF 
feature ID. The Bioconductor (version 3.1) 44 package DESeq2 (version 1.8.1) 
45 was used for differential expression analysis. We used the local fit parameter 
for dispersion fitting and obtained the significance with the DESeq2 negative 
binomial Wald test function. Genes with adjusted P < 0.05 after Benjamini-
Hochberg correction and a log2 foldchange < -0.59 or > 0.59 were considered 
significantly differentially expressed.  
 
Analysis of sphingolipids by LC-ESI-MS/MS. Serum and saline perfused 
lung tissues were collected from the mice. After the addition of internal 
standards (0.5 nmol each; Avanti Polar Lipids, Alabaster, AL, USA) the lipids 
were extracted and sphingolipids were quantified by LC-ESI-MS/MS (4000 
QTRAP, AB Sciex, Framingham, MA, USA) as described previously 46. 
 
Statistics. Statistical tests were selected to be appropriate for the data 
properties (e.g. normality or homogeneity of variance) and experimental design 
such the assumptions of the test would be met. Where multiple testing occurred 
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within a study, it was managed by controlling the family wise error rate as 
detailed in the associated figure legend. Integrative Data Analysis (also called 
Mega-Analysis) 47 was completed using R (package nlme v3.1) treating each 
experiment as a fixed effect. An iterative top down modelling strategy was 
implemented starting with the most comprehensive model (either Eq. [1], or [2]) 
appropriate for the collection strategy implemented and ensuring the model 
only included term where the terms could be independently assessed.  
Y=β0 + β1Sex + β2Experiment + β3Genotype + β4Sex*Genotype       [Eq.1]    
 
Y=β0 + β2Experiment + β3Genotype     [Eq. 2] 
 
The optimisation process first selected a covariance structure for the residual, 
then the model was reduced by removing non-significant fixed effects, and 
finally the genotype effect was tested and model diagnostics visualised. For the 
hypothesis test of primary interest, the impact of genotype, the per-comparison 
error rate threshold P values were adjusted to account for the multiple 
comparisons to control the family wise error rate to 5% using the Hochberg 
method 48.  
 
Bioinformatic analysis of molecular functions and phenotype. Using the 
Mouse Genome Informatics (MGI) portal (http://www.informatics.jax.org) all 
810 mutant lines screened were separated into unique symbols (to separate 
out microRNA clusters) and annotated with molecular function using the Gene 
Ontology (GO) batch query selecting the GO_Slim annotations. Phenotypic 
information was pulled from MGI as a batch query (MGI 6.06 release date 5th 
October 2016) and supplemented with annotations from the International 
Mouse Phenotyping Consortium (IMPC – release 4.3 26th April 2016) portal 
  32 
(http://www.mousephenotype.org). The reported mammalian phenotype (mp) 
terms returned were collapsed to the top-level term for the generation of the 
heatmap. We are not able to discriminate between no phenotype detected and 
no phenotypic data present, thus both outcomes are represented with a blue 
cell with the presence of phenotypes indicated by the red cell. 
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the integrative data analysis (IDA) are available on the online version of this 
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Number: ERP005660; ArrayExpress Accession Number: E-ERAD-287] with 
the results of the analysis shown in Source Data Table 1 (available on the online 
version of this manuscript). 
 
EXTENDED DATA FIGURE LEGENDS 
Extended Data Figure 1 | Phenotyping mice deficient for members of the 
interferon regulatory factor (Irf) family. a, Experimental metastasis assay 
using B16-F10 cells in Irf1tm1a/tm1a, Irf5tm1e/tm1e, Irf7tm1a/tm1a and concurrent 
control female mice. Shown are representative data from 2 (Irf5), 4 (Irf1) or 6 
(Irf7) independent experiments. Symbols represent individual mice with 
horizontal bar at the mean. P values are from a Mann-Whitney test. b-e, 
Representative photographs showing B16-F10 metastatic colonies on the (b) 
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lungs of +/+ and Irf1tm1a/tm1a mice and (c-e) the presence of extra-pulmonary 
metastases in Irf1tm1a/tm1a mice (tissues from 3 mice shown). 
 
Extended Data Figure 2 | Spontaneous pulmonary metastases and 
primary tumour growth in Spns2 mice. a, Size measurements of 
spontaneous pulmonary HCmel12-mCherry melanoma cell metastases of male 
mice (n=10 per genotype, horizontal bars represent mean (of 50 individual 
metastases counted per genotype), one-way ANOVA with blocking factor of 
experiment, cumulative results of 2 independent experiments shown). b, 
Survival curve of +/+ and tm1a/tm1a male mice (n=10 per genotype) in a 
spontaneous metastasis assay using HCmel12-mCherry cells (Log-rank test 
(Mantel-Cox), cumulative results of 2 independent experiments shown). c, 
Growth of subcutaneously administered B16-BL6 cells in +/+ (4 male, 5 female) 
and tm1a/tm1a (5 male, 1 female) mice. Symbols represent mean ± SEM with 
a two-tailed unpaired t test with Welch’s correction used to compare the areas 
under the curve. d, Incidence of cancer in aged (>40 weeks) +/+ (n=15; 4 
males, 11 females) and tm1a/tm1a (n=18; 5 males, 13 females) mice. Statistical 
analysis was performed using a Fisher’s Exact test. 
 
Extended Data Figure 3 | Analysis of sphingoid base levels in Spns2 mice. 
Sphingoid base levels in the a, serum (+/+, n=5; tm1a/tm1a, n=4) and b, lungs 
(+/+, n=6; tm1a/tm1a, n=5) of male mice, data is mean ± SEM, multiple two-
tailed unpaired t tests with P value adjusted by the Holm-Sidak method with 
alpha set to 5%. Sph, sphingosine; DHSph, dihydrosphingosine; S1P, 
sphingosine-1-phosphate; DHS1P, dihydrosphingosine-1-phosphate. 
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Extended Data Figure 4 | Phenotypic characterisation of the 
haematopoietic system of Spns2 mice. a-c, The numbers of erythrocytes 
and platelets, monocytes, granulocytes and lymphocytes subsets present in the 
blood of naïve +/+ and tm1a/tm1a female mice (multiple two-tailed unpaired t 
tests with P value adjusted by the Holm-Sidak method with alpha set to 5%, 
data shown are representative of three independent experiments). d, Analysis 
of lymphocyte subsets in the liver of naïve +/+ and tm1a/tm1a female mice 
(multiple two-tailed unpaired t tests with P value adjusted by the Holm-Sidak 
method with alpha set to 5%, data shown are representative of three 
independent experiments). e-f, T and B lymphocyte numbers in the blood of 
male naïve (unstimulated) bone marrow chimaeras (unpaired two-tailed t test 
with Welch's correction, data shown are representative of two independent 
experiments). Symbols represent individual mice and horizontal bars represent 
mean. 
 
Extended Data Figure 5 | Characterisation of the phenotype of tm1c/tm1c; 
Lyve1 mice. a-b, Sphingoid base levels in the serum (a) or lung (b) of control 
and tm1c/tm1c; Lyve1cre/+ male mice (data is mean ± SEM, multiple two-tailed 
unpaired t tests with P value adjusted by the Holm-Sidak method with alpha set 
to 5%). Sph, sphingosine; DH-Sph, dihydrosphingosine; S1P, sphingosine-1-
phosphate; DH-S1P, dihydrosphingosine-1-phosphate. c, Lymphocyte subsets 
in the spleen, lymph node, lung and liver of +/+ and tm1a/tm1a male mice 
(symbols represent individual mice, horizontal bars represent mean, multiple 
two-tailed unpaired t tests with P value adjusted by the Holm-Sidak method with 
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alpha set to 5%, data shown are representative of three independent 
experiments). d, Experimental metastasis assay using MC-38 cells in control 
(n=9) and tm1c/tm1c; Lyve1cre/+ (n=5) in female mice. Data shown are mean ± 
SEM, Mann-Whitney test, representative of 3 independent experiments. 
 
Extended Data Figure 6 | T cell subsets in the lungs of Spns2 mice. The 
proportion of T cell subsets present in the lungs of naïve +/+ and tm1a/tm1a 
female mice (a-b) and control and tm1c/tm1c; Lyve1cre/+ male mice (c-d). 
Symbols represent individual mice, statistical analysis was performed using 
multiple two-tailed unpaired t tests with P value adjusted by the Holm-Sidak 
method with alpha set to 5%. Data shown are representative of three 
independent experiments. 
 
Extended Data Figure 7 | T cell subsets in the liver of Spns2 mice. The 
proportion of T cell subsets present in the liver of naïve +/+ versus tm1a/tm1a 
female mice and control versus tm1c/tm1c; Lyve1cre/+ male mice. Data are 
shown as percentage of parent CD4+ and CD8+ T cells (a, c, e, f) or percentage 
of CD45+ alive liver cells present (b, d). Symbols represent individual mice, 
statistical analysis was performed using multiple two-tailed unpaired t tests with 
P value adjusted by the Holm-Sidak method with alpha set to 5% with * 
indicating P value that is not considered significant after correcting for multiple 
testing. Data shown are representative of three independent experiments. 
 
Extended Data Figure 8 | Phenotyping of Spns2 lungs. a, Measurement of 
IFN-γ in lungs of MC-38-stimulated +/+ and tm1a/tm1a male mice (unpaired 
  37 
two-tailed t test with Welch’s correction). b-c, The proportion of NK cell subsets 
present in the lungs of naïve +/+ versus tm1a/tm1a female mice (b) and control 
versus tm1c/tm1c; Lyve1cre/+ male mice (c) (multiple two-tailed unpaired t tests 
with P value adjusted by the Holm-Sidak method with alpha set to 5%). Symbols 
represent individual mice, horizontal bars represent mean and data shown are 
representative of three independent experiments. 
 
Extended Data Figure 9 | Studies in T- and B-cell deficient mice. a, 
Measurement of lymphocyte subsets in the blood of +/+ and Rag2-/- mice 
(multiple two-tailed unpaired t tests with P value adjusted by the Holm-Sidak 
method with alpha set to 5%). b, Experimental metastasis assay using B16-
F10 cells in +/+ and Rag2-/- female mice (Mann-Whitney test). Symbols 
represent individual mice, horizontal bars represent mean and data shown are 
representative of three independent experiments. 
 
Extended Data Figure 10 | Characterisation of the leukocyte composition 
and phenotype in 4’ deoxypyridoxine (DOP)-treated mice. a-d, The number 
of leukocytes and T cell subsets present in the lungs of B16-F10 dosed glucose- 
or DOP-treated wildtype male mice presented as percentage of viable CD45+ 
lung leukocytes or percentage of parent CD4+ or CD8+ T cells (multiple unpaired 
t tests with P value adjusted by the Holm-Sidak method with alpha set to 5%). 
e, Experimental metastasis assay in B16-F10 dosed glucose- or DOP-treated 
wildtype female mice (Mann-Whitney test). Symbols represent individual mice, 
horizontal bars represent mean and data shown are representative of 2 
independent experiments. 
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SUPPLEMENTARY INFORMATION TABLES 
 
SI Table 1 | Results of the experimental metastasis assay from stage 1 of 
the screen. A mutant (Mut) mouse line progressed to stage 2 if the metastatic 
ratio was ≤ 0.6 or ≥ 1.6 and P ≤ 0.0175 (Mann-Whitney test), and additional 
cohorts were tested. Where multiple cohorts were tested: (i) data is shown for 
the results from the first cohort, (ii) those with a significant results by Integrative 
Data Analysis (P < 0.01) are in red/green font (depending if 
decreased/increased metastasis), and (iii) those without significant results by 
Integrative Data Analysis (P > 0.01) are in blue font. P- and U-value listed in 
the table is from a Mann-Whitney test. F, female; M, male; Mut, mutant; WT, 
wildtype. 
 
SI Table 2. Results of the Integrative Data Analysis (IDA). IDA was 
performed on experimental metastasis assay data from mutant mouse lines 
tested in ≥2 independent cohorts. Shown in the top box are mutant lines that 
were significant from stage 1 of the screen (39/810, 5%), and were found to be 
significant by IDA (P < 0.01; 23/39, 59%); termed “hit”. Green indicates mice 
with an increased metastatic burden and red indicates mice with a decreased 
metastatic burden (the magnitude of the burden is indicated by the "genotype 
effect"). The genes are listed in order of "genotype effect". Shown in the middle 
box (in blue) are mutant lines that were significant from stage 1 of the screen, 
and were not found to be significant by IDA (P > 0.01; 16/39, 41%); termed 
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“false positive”. Shown in the bottom box (in black) are mutant lines which were 
not significant from stage 1 of the screen (102/810, 12%) for which additional 
cohorts were tested to ensure the selection criteria from stage 1 was not too 
stringent; termed “repeated negative”. F, female; M, male; SE, standard error. 
 







Source Data Table 1. Results of analysis of RNAseq data. Differentially 
expressed genes in B16-F10-mCherry cells isolated from the lungs of 
tm1a/tm1a mice relative to those from +/+ mice 24 hours after administration 
(n=5 per genotype).   
